Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|January 14, 2021
- Ophthalmology Times: January 2021
- Volume 46
- Issue 1
Seeing [duck floatie] floaters
Author(s)Jon Carter
Check out the latest cartoon!
Advertisement
Articles in this issue
over 5 years ago
Research is unfolding the proteins in retinitis pigmentosaover 5 years ago
Physicians discuss advancements in the treatment of wet AMDover 5 years ago
Developments in glaucoma offering hope, optionsover 5 years ago
Anti-VEGF medications may cause systemic complications in ROPover 5 years ago
Transscleral laser therapy device simplifies procedureover 5 years ago
It takes a village to beat visual system diseases in childrenover 5 years ago
The value of new diagnostics and personalized medicineAdvertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
AAO 2026: Tinlarebant in Stargardt disease: Jacque Duncan, MD, on DRAGON results
2
PRIMA at 3 years: Early surgical risk, durable vision gains in GA
3
AAO 2026: What the evidence really shows about nutrition and the eye
4
AAO 2026: Vamikibart shows sustained gains in uveitic macular edema as FDA accepts BLA
5